as Representatives of the several Underwriters to be named in the within- mentioned Underwriting AgreementUnderwriting Agreement • July 6th, 2017 • Novartis Bioventures LTD • Pharmaceutical preparations
Joint Filing AgreementJoint Filing Agreement • July 6th, 2017 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock beneficially owned by each of them of Aileron Therapeutics, Inc. This Joint Filing Agreement shall be included as an Exhibit to such Schedule 13D.
